Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist

J Urol. 2024 Mar;211(3):482. doi: 10.1097/JU.0000000000003831. Epub 2024 Jan 5.

Authors

Marc B Garnick¹, Jason Hafron², E David Crawford³

Affiliations

¹ Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Michigan Institute of Urology, Troy, Michigan.
³ University of California San Diego, Koman Family Outpatient Pavilion, San Diego, California.

PMID: 38179977
DOI: 10.1097/JU.0000000000003831

No abstract available

MeSH terms

Cardiovascular Diseases* / chemically induced
Cardiovascular Diseases* / epidemiology
Gonadotropin-Releasing Hormone
Heart Disease Risk Factors
Humans
Male
Prostatic Neoplasms* / drug therapy
Risk Factors

Substances

Gonadotropin-Releasing Hormone